Abg Innovation Capital Partners Iii Gp LTD Castle Biosciences Inc Transaction History
Abg Innovation Capital Partners Iii Gp LTD
- $782,000
- Q1 2025
A detailed history of Abg Innovation Capital Partners Iii Gp LTD transactions in Castle Biosciences Inc stock. As of the latest transaction made, Abg Innovation Capital Partners Iii Gp LTD holds 36,747 shares of CSTL stock, worth $596,403. This represents 93.99% of its overall portfolio holdings.
Number of Shares
36,747
Previous 36,747
-0.0%
Holding current value
$596,403
Previous $979,000
24.92%
% of portfolio
93.99%
Previous 92.1%
Shares
4 transactions
Others Institutions Holding CSTL
# of Institutions
192Shares Held
26.7MCall Options Held
9.5KPut Options Held
5K-
Black Rock Inc. New York, NY3.04MShares$49.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.05MShares$33.2 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.47MShares$23.8 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.27MShares$20.5 Million2.07% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.2MShares$19.5 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $427M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...